Merck winds down Phase 3 TIGIT/PD-1 combo study due to safety-related dropouts
A large number of patient dropouts caused by immune side effects have forced Merck to end a late-stage trial of its anti-TIGIT drug vibostolimab in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
